bioMérieux Receives CE Mark for Two New Rapid PCR Tests
bioMérieux has announced the acquisition of the CE mark under the IVDR directive for two diagnostic tests for respiratory and pharyngeal infections. These multiplex PCR tests, compatible with bedside use, are now authorized in Europe for deployment outside of traditional laboratories.
The BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel and BIOFIRE® SPOTFIRE® R/STplus Panel Mini have received the CE mark under the IVDR, including the 'Near-Patient Testing' classification allowing use at the point of care. These multiplex PCR tests can simultaneously detect pathogens responsible for respiratory infections and sore throats in about 15 minutes. The standard panel detects 15 pathogens, while the Mini panel identifies 6, including human rhinovirus/enterovirus, Streptococcus A, influenza A/B viruses, RSV, and SARS-CoV-2. Samples can be taken using nasopharyngeal, oropharyngeal swabs, or, for the Mini panel, anterior nasal swabs.
Enhancement of Respiratory Diagnostic Offerings
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The BIOFIRE® SPOTFIRE® R/STplus Panel replaces the previous version marketed with the CE mark under the IVDD directive. bioMérieux is simultaneously introducing the R/STplus Panel Mini, enhancing its respiratory diagnostic offerings in Europe. Both tests will be available in the second quarter of 2026 in countries recognizing the CE mark, and will then be deployed in other regions outside the United States according to local regulations.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
